Evidence map›Paper›PMID 26043762›Full record

ArticleDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2016

Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

S M Brankley, K C Halling, S M Jenkins, M R Timmer, P G Iyer, T C Smyrk, E G Barr Fritcher, J S Voss, B R Kipp, M B Campion and 3 more

Abstract read
In one paragraph

Article in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Biomarker Use in Barrett's Esophagus Surveillance.The American journal of gastroenterology · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  7. Article
  8. Review
  9. Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

S M BrankleyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
K C HallingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
S M JenkinsDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
M R TimmerDepartment of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
P G IyerDepartment of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
T C SmyrkDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
E G Barr FritcherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
J S VossDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
B R KippDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
M B CampionDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
L S LutzkeDepartment of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
D M MinotDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
K K WangDepartment of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Biomarkers in Phototherapy of Barrett's EsophagusR01CA097048 · NCI · MAYO CLINIC ROCHESTER · PI WANG, KENNETH K · 2002 to 2010
$2.3M
Endoscopic Therapy of Early Cancer in Barretts EsophagusR01CA111603 · NCI · MAYO CLINIC ROCHESTER · PI WANG, KENNETH K · 2005 to 2009
$1.6M
Novel Method of Surveillance in Barrett's EsophagusR21CA122426 · NCI · MAYO CLINIC ROCHESTER · PI WANG, KENNETH K · 2007 to 2008
$298k
NCATS NIH HHS UL1 TR000135NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA097048NCI NIH HHS R01 CA111603NCI NIH HHS R21 CA122426
6 · The paper itself

Abstract

Barrett's esophagus (BE) with high-grade dysplasia (HGD) defines a group of individuals at high risk of progression to esophageal adenocarcinoma (EA). Fluorescence in situ hybridization (FISH) has been shown to be useful for the detection of dysplasia and EA in endoscopic brushing specimens from BE patients. The aim of this study was to determine whether FISH in combination with histological findings would further identify more rapid progressors to EA. This is a retrospective cohort study of high-risk patients, having a history of biopsy-confirmed HGD without EA, with an endoscopic brushing specimen analyzed by FISH while undergoing endoscopic surveillance and treatment between April 2003 and October 2010. Brushing specimens were assessed by FISH probes targeting 8q24 (MYC), 9p21 (CDKN2A), 17q12 (ERBB2), and 20q13 (ZNF217) and evaluated for the presence of polysomy, defined as multiple chromosomal gains (displaying ≥ 3 signals for ≥ 2 probes). Specimens containing ≥ 4 cells exhibiting polysomy were considered polysomic. HGD was confirmed by at least two experienced gastrointestinal pathologists. Of 245 patients in this study, 93 (38.0%) had a polysomic FISH result and 152 (62.0%) had a non-polysomic FISH result. Median follow-up was 3.6 years (interquartile range [IQR] 2-5 years). Patients with a polysomic FISH result had a significantly higher risk of developing EA within 2 years (14.2%) compared with patients with a non-polysomic FISH result (1.4%, P < 0.001). These findings suggest that a polysomic FISH result in BE patients with simultaneous HGD identifies patients at a higher risk for developing EA compared with those with non-polysomy.

Indexed as

AdenocarcinomaAgedBarrett EsophagusCohort StudiesCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18Disease ProgressionDNA ProbesErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagoscopyFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18DNA ProbesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMYC protein, humanProto-Oncogene Proteins c-mycTrans-ActivatorsZNF217 protein, humanBarrett's esophaguscytologyesophageal adenocarcinomaFISHpolysomy

Identifiers

PMID26043762
PMCPMC5563668
OpenAlexW1581591622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.